Table 3.
Outcome per subgroup
| P2 (N = 3) |
P3 (N = 3) |
P4 (N = 6) |
C3 (N = 11) |
C4 (N = 19) |
|
|---|---|---|---|---|---|
| Time to sero-negativity (days)—median (min–max)a | 116 (88–143) | 71 (56–85) | 84 (58–127) | 41 (14–129) | 56 (28–126)c |
| Peak binding antibody levels (BAU mL−1)—median (min–max)b | 675 (235–736) | 409 (174–525) | 511 (313–758) | 170 (93–276) | 369 (212–736) |
| Breakthrough infection—no. | 1 | – | 1 | – | 1 |
| SAEs reported—no. | – | – | – | 1 | 1 |
BAU binding antibody units, IQR interquartile range, SAEs serious adverse events
a36 patients were followed until antibodies were negative. P2: one missing patient had a breakthrough infection, C4: one missing patient had a breakthrough infection
bMeasured one hour after infusion
cC4: two missing due to logistical issues